Otsuka Pharmaceutical Co.,Ltd. News Release http://www.otsuka.com/en/hd_release/otsuka_release/ en Wed, 08 Sep 2010 01:39:31 +0900 Wed, 08 Sep 2010 01:39:31 +0900 Construction of 'OPS-5', New Plant to Manufacture Active Pharmaceutical Ingredients in Saga Factory Completed on September 1 http://www.otsuka.co.jp/en/release/2010/0901_01.html Wed, 01 Sep 2010 14:00:00 +0900 Publication of Environmental and Social Report 2010- Featuring approaches to help build a low-carbon, recycling-oriented society, development of environment-conscious products and social action programs - http://www.otsuka.co.jp/en/release/2010/0831_01.html Tue, 31 Aug 2010 14:00:00 +0900 21st Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki '10 on August 13, 2010 http://www.otsuka.co.jp/en/release/2010/0816_01.html Mon, 16 Aug 2010 00:00:00 +0900 E Keppra® (levetiracetam) receives regulatory approval in Japan http://www.otsuka.co.jp/en/release/2010/0723_01.html Fri, 23 Jul 2010 16:00:00 +0900 SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase http://www.otsuka.co.jp/en/release/2010/0712_01.html Mon, 12 Jul 2010 16:00:00 +0900 GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration http://www.otsuka.co.jp/en/release/2010/0630_01.html Wed, 30 Jun 2010 15:00:00 +0900 Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010 http://www.otsuka.co.jp/en/release/2010/0614_01.html Mon, 14 Jun 2010 00:00:00 +0900 Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF:39KB) http://www.otsuka.co.jp/en/release/2010/pdf/0610_01_01.pdf Thu, 10 Jun 2010 00:00:00 +0900 Four-Year Follow-Up Data for SPRYCEL® (dasatinib)Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec® http://www.otsuka.co.jp/en/release/2010/0609_01.html Wed, 09 Jun 2010 20:00:00 +0900 SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase http://www.otsuka.co.jp/en/release/2010/0608_01.html Tue, 08 Jun 2010 17:00:00 +0900